Learn more here about our client impact projects in Contract Negotiation services for biotech, pharma, and CROs.
A privately-owned biotechnology company, backed by leading life science investors and over £270M in private financing, faced significant challenges running a global Phase 3 rare disease trial with a large CRO. With slow site activation, recruitment delays, and increasing board concerns over study feasibility, the sponsor engaged Seuss+ to restore confidence, accelerate timelines, and protect budget integrity.
Avillion, a late-phase therapeutic project partner accelerating market availability, required guidance for CRO selection across two clinical trials. With ambitious delivery timelines and multiple suppliers involved, Avillion needed both robust vendor selection and a governance framework to manage multiple CROs effectively.
A high-potential biotech, entering Phase 2 with an ambitious formulation study, faced late-stage strategic changes that rendered its original CRO unsuitable. Operating with a lean team and under competitive pressures, the sponsor required rapid CRO transition, complete vendor oversight, and embedded operational expertise to stay on schedule and protect data integrity.
We can help you